IDO1 and neoplasm: The release of immunosuppressive factors such as IL-10, TGF-β, and indoleamine 2,3-dioxygense (IDO) by tumor targets has also been reported, which can suppress the adaptive anti-tumor immune response or skew the immune response toward a Th2 response with significantly less anti-tumor capacity (95–99) (Figure 2).